Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biocircuits Corp.

This article was originally published in The Gray Sheet

Executive Summary

Burlingame, California-based developer of immunoassay diagnostic products files registration statement with the Securities and Exchange Commission for an offering of 2.5 mil. shares of common stock. The company expects to use net proceeds from the offering for R&D, adding technical personnel and capital equipment, relocating and expanding facilities, and establishing manufacturing and sales and marketing capabilities. The firm's initial development work is focusing on the Biocircuits I point-of-care system ("The Gray Sheet" April 13, 1992, p. 12). The company projects filing a 510(k) for use of the Biocircuits I with T4 and T Uptake cartridges in mid-1993. Biocircuits went public in May/June and netted approximately $9.3 mil. from an offering of 2.1 mil. shares. The firm raised an additional $3.6 mil. from an offering of 700,000 shares in December. The company estimates that proceeds from the current offering will be $16.7 mil., assuming a selling price of $7.25 per share; the stock recently has been trading in the $6 to $7 range. Existing capital together with proceeds from this offering "will be adequate to satisfy [Biocircuits'] requirements at least through the end of 1994," the filing states. The offering is being underwritten by Hambrecht & Quist and Oppenheimer & Co....

You may also be interested in...

Purell Battling Class Actions Over Disease Claims While World Scrambles To Increase Hand Sanitizer Supplies

Leading chemical firms, beauty and consumer health companies, even distilleries and medical marijuana cultivators are adapting operations to meet global demand for hand sanitizers amid the COVID-19 pandemic. Meanwhile, plaintiff’s attorneys are busy with multiple class actions against Purell manufacturer GOJO Industries for alleged false advertising following a January warning letter to the firm from the US FDA.

FDA's Emergency Use Authorization for Malaria Drugs Could Hinder Trials of Other COVID-19 Treatments

Questions linger about the role the White House played in pushing the EUA, which comes with large product donations from Bayer and Sandoz that are expected to alleviate supply chain pressures for the drugs. 

US FDA Commissioner Hahn’s Star Turn: Baptism By Fire Turns Perilous

FDA Commissioner Stephen Hahn was added to the White House's pandemic task force as the outbreak grew, but he remained in a background role. That all changed the morning of 18 March, when President Trump tweeted: “I will be having a news conference today to discuss very important news from the FDA concerning the Chinese Virus!” A day later, Hahn was standing with Trump at the podium for the now-daily press briefings on Covid-19.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts